INTERFERON BETA DRUGS MARKET ANALYSIS

Market Challenges And Opportunities

Global Interferon Beta Drugs Market - Key Players

Global Interferon Beta Drugs Market - Restraint

• Inefficiencies to treat COVID- 19: In an international open-label trial published in the New England Journal of Medicine, a weekly medical journal published by the Massachusetts Medical Society, interferon beta-1a does not reduce mortality, hospitalization duration, or ventilation initiation in coronavirus disease 2019 patients. As a part of the study, 11,266 patients from hospitals between March 22 and October 4, 2020, in 30 countries were randomly assigned to receive either remdesivir (n=2750), hydroxychloroquine (n=954), lopinavir (n=1411), interferon (n=2063), or no trial drug (n=4088). This restraint can be overcome by the introduction of the drug as a treatment against COVID-19, but only after the recommendation of the consulting physician or healthcare provider.

• Potential side-effects of interferon therapy: Barriers like the serious and mild side-effects of interferon therapy are restraining the growth of the market. For instance, Avonex (interferon beta-1a) can have mild side effects like headaches, the common cold, dizziness, diarrhea, nausea, and chest pain. This can be overcome by taking the dose of the drug strictly as per the recommendation of the physician.

Interferon Beta Drugs Market Report Coverage 

Report Coverage	Details
Base Year:	2022	Market Size in 2023:	US$ 4.22 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 to 2030
Forecast Period 2023 to 2030 CAGR:	4.0%	2030 Value Projection:	US$ 5.55 Bn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa